MCHB-1
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H37N3O2 |
| Molar mass | 447.623 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MCHB-1 is a benzimidazole derived drug which was researched as an analgesic but never developed for medical use. It acts as a potent agonist of the CB2 receptor, with an EC50 of 0.52nM at CB2, and ~30x selectivity over CB1 (Ki of 110nM at CB1 vs 3.7nM at CB2).[1][2] It has been sold online as a designer drug, first being identified in Germany in December 2013.[3]
See also
References
- ^ Pagé D, Balaux E, Boisvert L, et al. Novel benzimidazole derivatives as selective CB2 agonists. Bioorganic & Medicinal Chemistry Letters 2008; 18(13): 3695-3700. PMID 18522867 doi:10.1016/j.bmcl.2008.05.073
- ^ Yu XH, Cao CQ, Martino G, et al. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 2010; 151(2): 337-344. doi:10.1016/j.pain.2010.07.019
- ^ Westphal F, Sönnichsen FD, Knecht S, Auwärter V, Huppertz L. Two thiazolylindoles and a benzimidazole: Novel compounds on the designer drug market with potential cannabinoid receptor activity. Forensic Sci. Int. 2015; 249: 133–147. doi:10.1016/j.forsciint.2015.01.014
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |